A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea — SPRY  

Secondary Amenorrhea Clinical Trial

Official title: A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding After Administration of TX-12-002-HR in Estrogen-Primed Women With Secondary Amenorrhea

Status Terminated

Clinical Trial Summary

This study will be a Phase 3, randomized, three-cycle, double-blind, placebo-controlled, parallel group, multiple-dose design.

The study design has four phases: Screening Period; Open-Label Estrogen-Priming Period (Run-In Period); Blinded Treatment Period; and Follow-Up. The Open Label Priming Period and Blinded Treatment Period cover a total of three 28-day cycles. Clinical evaluations will be performed at the following time points:

Screening Period:

• Screening Period (approximately 42 Days)

Open-Label Estrogen Priming Period (Run In Period):

• Visit 1 Baseline (Cycle 1, Day 1)

• Telephone Interview (Cycle 1, Day 28 [- 3 d to ±1d])

Blinded Treatment Period:

• Visit 2 Randomization (Cycle 2, Day 12 [±2d])

• Visit 3 Interim (Cycle 3, Day 12 [±2d])

• Visit 4 End of treatment (Cycle 3, Day 24 [±1d])

Follow-Up Period:

• Visit 5 Follow-Up (Approximately 10 days after the last treatment)

• Telephone Interview (Approximately 2-4 weeks after completion of progestin course) (Only applies to subjects receiving an approved progestin therapy for proliferative endometrium, as determined by biopsy.)

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Amenorrhea
• Neoplasm Metastasis
• Secondary Amenorrhea

• NCT number: NCT02019589
• Study type: Interventional
• Source: TherapeuticsMD
• Status: Terminated
• Phase: Phase 3
• Start date: January 20, 2014
• Completion date: October 31, 2014